Phase 1 Growth Clinical Trials
18 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–18 of 18 trials
Recruiting
Phase 1
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Phase 1Clear Cell CarcinomaGrowth Factor
M.D. Anderson Cancer Center30 enrolled1 locationNCT07072234
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
SafetyTolerabilityAdult Growth Hormone Deficiency
Changchun GeneScience Pharmaceutical Co., Ltd.64 enrolled1 locationNCT07016802
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Not Yet Recruiting
Phase 1
A Study of the Safety, Pharmacokinetics and Exploratory Efficacy of RC220 in Combination with Osimertinib in Adult Patients with Non- Small Cell Lung Cancer.
Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations
Racura Oncology Ltd.40 enrolled1 locationACTRN12626000325303
Recruiting
Phase 1Phase 2
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Glioblastoma MultiformeGlycolytic IndexEpidermal Growth Factor Receptor
Jonsson Comprehensive Cancer Center50 enrolled1 locationNCT06059690
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd.141 enrolled4 locationsNCT06975618
Recruiting
Phase 1
Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth
Small Intestinal Bacterial Overgrowth
McMaster Children's Hospital20 enrolled2 locationsNCT05967871
Recruiting
Phase 1
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
Small Intestinal Bacterial Overgrowth
Envivo Bio Inc34 enrolled1 locationNCT06298409
Recruiting
Phase 1Phase 2
Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
National University of Natural Medicine32 enrolled1 locationNCT06721884
Recruiting
Phase 1Phase 2
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
Spasticity, MuscleSpastic ParaplegiaMicrocephaly+3 more
Elpida Therapeutics SPC4 enrolled1 locationNCT05518188
Recruiting
Phase 1
Comparison of Skeletal Effects of Herbst and Invisalign MA in Growing Patients With KLass II Malocclusion
Mandibular Growth Stimulation
Université Libre de Bruxelles30 enrolled2 locationsNCT06409923
Completed
Phase 1
A trial comparing ACP-011 administered as a single dose via a syringe and needle versus an auto-injector
Growth failure in children due to Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S26 enrolled1 locationACTRN12617001471370
Recruiting
Phase 1
5 year study of 6 children each year with vascular anomalies who have severe complications failing to respond to the usual treatments will be offered a new use of an old medication- sirolimus
PIKC3A related overgrowth syndrome (PROS)Vascular tumours (tufted angiomas and kaposiform haemangioendotheliomas)Complex lymphatic malformations+2 more
Sydney Children's Hospital, Randwick30 enrolled1 locationACTRN12616000943448
Completed
Phase 1
A Randomised, Placebo Controlled, Double-Blind, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1103 in Healthy Adult Male Subjects
ATL1103 is being developed as a potential treatment for diseases of excessive growth hormone and insulin-like growth hormone (IGF)-I action, including the condition acromegaly.
Antisense Therapeutics Limited36 enrolled1 locationACTRN12611000854932